Novartis has bulked up its cardiology pipeline with a $1.4 billion takeover of Tourmaline Bio and its phase 3-ready drug for atherosclerotic cardiovascular disease (ASCVD).

诺华通过以14亿美元收购Tourmaline Bio及其处于第3阶段的动脉粥样硬化性心血管疾病（ASCVD）药物，加强了其心脏病学研发管线。

The Swiss pharma group has launched a $48-per-share tender offer for New York-based Tourmaline, attracted by the lustre of primary asset pacibekitug, an anti-IL-6 antibody that is being developed to suppress systemic inflammation in atherosclerosis – sometimes described as a chronic inflammatory vascular disease..

瑞士制药集团已发起每股48美元的收购要约，对象是位于纽约的托玛琳公司。此次收购受到主要资产pacibekitug（一种正在开发用于抑制动脉粥样硬化全身炎症的抗IL-6抗体）的吸引力驱动——动脉粥样硬化有时被描述为一种慢性炎症性血管疾病。

In May, Tourmaline reported top-line data from the phase 2 T

今年五月，图尔马琳报告了二期T的顶线数据

RANQUILITY

静谧

trial of pacibekitug, showing that it was able to achieve 85%-plus reductions in high-sensitivity C-reactive protein (hs-CRP) – a biomarker for inflammation – with subcutaneous dosing every three months. The overall incidence rates of adverse events and serious adverse events were comparable to placebo, it said..

Pacibekitug的试验显示，每三个月通过皮下注射给药，可使高敏C反应蛋白（hs-CRP）这一炎症生物标志物减少85%以上。该公司表示，不良事件和严重不良事件的总体发生率与安慰剂相当。

Tourmaline claimed its data shows best-in-class potential for the drug, whose nearest competitor is Novo Nordisk's IL-6 inhibitor ziltivekimab, acquired as part of its $2.1 billion takeover of Corvidia in 2020, which is already in phase 3 testing but requires monthly dosing.

碧玺公司声称其数据显示该药物具有同类最佳的潜力，其最接近的竞争对手是诺和诺德的IL-6抑制剂ziltivekimab，该药物是诺和诺德在2020年以21亿美元收购Corvidia时获得的，目前已进入三期试验阶段，但需要每月给药。

'With no widely adopted anti-inflammatory therapies currently available for cardiovascular risk reduction, pacibekitug represents a potential breakthrough in addressing residual inflammatory risk in ASCVD with a differentiated mechanism of action targeting IL-6,' said Shreeram Aradhye, Novartis' chief medical officer..

“由于目前尚无广泛采用的抗炎疗法可用于降低心血管风险，帕西贝库单抗通过一种针对IL-6的独特作用机制，有望在解决动脉粥样硬化性心血管疾病（ASCVD）残留炎症风险方面取得突破，”诺华首席医疗官Shreeram Aradhye表示。

Rumours

谣言

emerged last month that Novartis was on the cusp of an acquisition, although they linked the Basel-based group to RNA therapeutic specialist Avidity Biosciences rather than Tourmaline.

上个月浮出水面的消息显示，诺华即将进行收购，尽管他们将总部位于巴塞尔的集团与RNA治疗专业公司Avidity Biosciences联系在一起，而不是Tourmaline。

Novartis has been investing hard in deals to build its pipeline, and this year alone has already bought kidney drug specialist

诺华一直在大力投资交易以构建其产品线，仅今年就已经收购了肾脏药物专家公司。

Regulus

轩辕十四

for up to $1.7 billion and atrial fibrillation therapy developer

高达17亿美元的心房颤动治疗开发商

Anthos

Anthos

in a $3.1 billion transaction, fulfilling a pledge by chief executive Vas Narasimhan to keep up a steady pace in bolt-on, sub-$5 billion transactions.

在一笔31亿美元的交易中，首席执行官瓦斯·纳拉西曼兑现了保持稳步进行低于50亿美元的附加收购交易的承诺。

Last year. the company also snapped up

去年，该公司还迅速收购了

Kate Therapeutics

凯特治疗学

for $1.1 billion,

以11亿美元的价格，

Mariana Oncology

玛丽安娜肿瘤学

for around $1.75 billion, and

大约17.5亿美元，而且

MorphoSys

莫尔普斯

for $2.9 billion.

以29亿美元的价格。

Its efforts to build in the cardiovascular category come as it has started facing generic competition to heart failure therapy

其在心血管领域加大投入的举措，正值其心力衰竭治疗开始面临仿制药竞争之际。

Entresto

恩格列净

(sacubitril/valsartan), which brought in $7.8 billion in sales last year.

（沙库比曲/缬沙坦），去年带来了78亿美元的销售额。

The Tourmaline deal is expected to close in the fourth quarter, subject to the usual regulatory reviews, with the company operating as an indirect, wholly owned subsidiary of Novartis thereafter. The offer represents a 59% premium to Tourmaline's closing share price yesterday.

Tourmaline交易预计将在第四季度完成，但需接受常规的监管审查，之后该公司将成为诺华的间接全资子公司。此报价较Tourmaline昨日收盘股价溢价59%。

'Our mission at Tourmaline has been to establish new standards of care in areas of high unmet medical need, and today's transaction announcement both underscores our commitment to that focus and also delivers compelling shareholder value,' said Sandeep Kulkarni, the company's co-founder and CEO.

“Tourmaline 的使命是在高度未满足医疗需求的领域建立新的护理标准，而今天的交易公告不仅强调了我们对此目标的承诺，同时也为股东带来了引人注目的价值，”公司联合创始人兼首席执行官桑迪普·库尔卡尼表示。

Image by

图片由

SerenityArt

宁静艺术

from

从

Pixabay

Pixabay